. 2016 Mar;6(1):e129–e132. doi: 10.1055/s-0036-1579646

Table 1. Selected demographic data and outcomes.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Blood type	O−	A Rh−	B Rh−	O−	A Rh−
Antibody	Anti-D, anti-C	Anti-D	Anti-D, anti-C	Anti-D, anti-C	Anti-D, anti-C, anti-E, anti-Fy^a
History of IV drug use?	Yes	Yes	Yes	Yes	Yes
Current drug use?	Methadone	Buprenorphine	Methadone	Buprenorphine	Illicit narcotics
Hepatitis C infection?	No	Yes	No	Yes	Yes
Antibodies in prior pregnancy?	No	No	No	No	NA
Prior neonate/fetus with HDFN?	No	No	No	No	NA
RhIG in previous pregnancies?	Yes, per patient report	Yes, per patient report	Yes, per patient report	Yes, per patient report	NA
History of blood transfusion?	No	No	No	No	No
Fetal/neonatal blood type and antigen status	O + , C antigen +	A Rh+	O + , C antigen −	O + , C antigen +	O + , C antigen +, E and Fy^a antigen status undeterminable
Pregnancy complications	Hydrops fetalis at 32^6/7 wk, opted for delivery	Hydrops fetalis at 29^0/7 wk	HDFN at 30^4/7 wk	HDFN at 32^6/7 wk, opted for delivery	HDFN at 19^0/7 wk
Fetal/neonatal treatment	Neonatal exchange transfusions, IVIG therapy, and phototherapy	Seven intrauterine transfusions	Three intrauterine transfusions	Neonatal IVIG and phototherapy	Seven intrauterine transfusions

Abbreviations: HDFN, hemolytic disease of the fetus and newborn; IV, intravenous; IVIG, intravenous immunoglobulin; RhIG, Rh immune globulin.